Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,inventory,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,marketState,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,exchange,priceHint,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,FRPRF,19179000.0,180300992,3214855,,-4543908,,-5877449,3501110,157271,-6573030,-6573030,14336,-413,,,,1333542,157271,6730301,0,2029122,,-5877449,-5877449,6303000.0,210876000.0,10128000.0,38971000.0,2010000.0,1705000.0,49099000.0,479000.0,398000.0,-148235000.0,527000.0,13489000.0,-24149000.0,2252000.0,11990000.0,8509000.0,-24149000.0,6211000.0,20844000.0,6062000.0,4540000.0,,981030,1050,79014,3383901,-339500,1537705,-746785,-4000,-4127737,364122,-3413,9557,707908,1767183,-1414478,3724,12335000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,1.21 - 1.21,1.21,finmb_256832485,Other OTC,4D pharma plc,USD,18664,166,0.00999999,0.008333325,1.2 - 2.3,-1.0899999,-0.473913,1.2,2.3,-14400000,False,False,USD,POST,1.2169445,-0.006944418,-0.005706438,1.4982102,-0.28821015,-0.19236964,218164208,15,America/New_York,EDT,4D PHARMA PLC,1.21,1629898578,0.0,1.21,1.21,1.21,1018,0,PNK,4,us_market,2.92,,,2.3,1.2,1.2169,1.4982,18.66k,166,180.3M,,87.74M,35.72%,27.01%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,"-5,175.22%",-49.64%,-86.93%,690k,0.01,16.90%,690k,-34.14M,-30.5M,,,11.99M,0.09,1.19M,3.06,2.45,,-27.27M,-17.74M,Value,LS1 2JZ,Healthcare,92,"4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.",Leeds,44 11 3895 0130,1609372800,United Kingdom,http://www.4dpharmaplc.com,86400,9 Bond Court,Biotechnology,5th Floor
t-1,FRPRF,19179000.0,180300992,3662775,,-5109813,,-6372548,3659963,167191,-7169126,-7169126,13578,-233,,,,1262736,167191,7336316,0,2059313,,-6372548,-6372548,6303000.0,210876000.0,10128000.0,38971000.0,2010000.0,1705000.0,49099000.0,479000.0,398000.0,-148235000.0,527000.0,13489000.0,-24149000.0,2252000.0,11990000.0,8509000.0,-24149000.0,6211000.0,20844000.0,6062000.0,4540000.0,,981715,-5081,74469,4115693,-339500,2331249,-523474,-4000,-4630086,386414,-3233,9052,670503,1709975,-1330651,-2047,12335000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,1.21 - 1.21,1.21,finmb_256832485,Other OTC,4D pharma plc,USD,18664,166,0.00999999,0.008333325,1.2 - 2.3,-1.0899999,-0.473913,1.2,2.3,-14400000,False,False,USD,POST,1.2169445,-0.006944418,-0.005706438,1.4982102,-0.28821015,-0.19236964,218164208,15,America/New_York,EDT,4D PHARMA PLC,1.21,1629898578,0.0,1.21,1.21,1.21,1018,0,PNK,4,us_market,2.92,,,2.3,1.2,1.2169,1.4982,18.66k,166,180.3M,,87.74M,35.72%,27.01%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,"-5,175.22%",-49.64%,-86.93%,690k,0.01,16.90%,690k,-34.14M,-30.5M,,,11.99M,0.09,1.19M,3.06,2.45,,-27.27M,-17.74M,Value,LS1 2JZ,Healthcare,92,"4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.",Leeds,44 11 3895 0130,1609372800,United Kingdom,http://www.4dpharmaplc.com,86400,9 Bond Court,Biotechnology,5th Floor
t-2,FRPRF,17276000.0,180300992,6209000,,-7844500,,-6863000,2202000,137500,-8263000,-8263000,-10500,-44000,,,,-981500,137500,8400500,0,418500,,-6863000,-6863000,14181000.0,130186000.0,8489000.0,31457000.0,,,39946000.0,274000.0,,-100718000.0,966000.0,,1715000.0,191000.0,10027000.0,6496000.0,1715000.0,5061000.0,20513000.0,10274000.0,6423000.0,212000.0,9500,-85000,-63000,10144000,-339500,11000000,3095500,-4000,-6963500,309000,2500,-7000,-518500,-793000,1162000,-80000,14017000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,1.21 - 1.21,1.21,finmb_256832485,Other OTC,4D pharma plc,USD,18664,166,0.00999999,0.008333325,1.2 - 2.3,-1.0899999,-0.473913,1.2,2.3,-14400000,False,False,USD,POST,1.2169445,-0.006944418,-0.005706438,1.4982102,-0.28821015,-0.19236964,218164208,15,America/New_York,EDT,4D PHARMA PLC,1.21,1629898578,0.0,1.21,1.21,1.21,1018,0,PNK,4,us_market,2.92,,,2.3,1.2,1.2169,1.4982,18.66k,166,180.3M,,87.74M,35.72%,27.01%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,"-5,175.22%",-49.64%,-86.93%,690k,0.01,16.90%,690k,-34.14M,-30.5M,,,11.99M,0.09,1.19M,3.06,2.45,,-27.27M,-17.74M,Value,LS1 2JZ,Healthcare,92,"4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.",Leeds,44 11 3895 0130,1609372800,United Kingdom,http://www.4dpharmaplc.com,86400,9 Bond Court,Biotechnology,5th Floor
t-3,FRPRF,17276000.0,180300992,6209000,,-7844500,,-6863000,2202000,137500,-8263000,-8263000,-10500,-44000,,,,-981500,137500,8400500,0,418500,,-6863000,-6863000,14181000.0,130186000.0,8489000.0,31457000.0,,,39946000.0,274000.0,,-100718000.0,966000.0,,1715000.0,191000.0,10027000.0,6496000.0,1715000.0,5061000.0,20513000.0,10274000.0,6423000.0,212000.0,9500,-85000,-63000,10144000,-339500,11000000,3095500,-4000,-6963500,309000,2500,-7000,-518500,-793000,1162000,-80000,14017000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,1.21 - 1.21,1.21,finmb_256832485,Other OTC,4D pharma plc,USD,18664,166,0.00999999,0.008333325,1.2 - 2.3,-1.0899999,-0.473913,1.2,2.3,-14400000,False,False,USD,POST,1.2169445,-0.006944418,-0.005706438,1.4982102,-0.28821015,-0.19236964,218164208,15,America/New_York,EDT,4D PHARMA PLC,1.21,1629898578,0.0,1.21,1.21,1.21,1018,0,PNK,4,us_market,2.92,,,2.3,1.2,1.2169,1.4982,18.66k,166,180.3M,,87.74M,35.72%,27.01%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,"-5,175.22%",-49.64%,-86.93%,690k,0.01,16.90%,690k,-34.14M,-30.5M,,,11.99M,0.09,1.19M,3.06,2.45,,-27.27M,-17.74M,Value,LS1 2JZ,Healthcare,92,"4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.",Leeds,44 11 3895 0130,1609372800,United Kingdom,http://www.4dpharmaplc.com,86400,9 Bond Court,Biotechnology,5th Floor
